Limits...
15-epi-lipoxin A4 reduces the mortality of prematurely born pups in a mouse model of infection-induced preterm birth.

Rinaldi SF, Catalano RD, Wade J, Rossi AG, Norman JE - Mol. Hum. Reprod. (2015)

Bottom Line: There are currently few effective therapies and therefore an urgent need for novel treatments.Although pretreatment with 15-epi-lipoxin A4 did not delay LPS-induced PTL, there was a significant reduction in the mortality amongst prematurely delivered pups (defined as delivery within 36 h of surgery) in mice treated with 15-epi-lipoxin A4 prior to LPS treatment, compared with those receiving LPS alone (P < 0.05).Quantitative real-time (QRT)-PCR analysis of utero-placental tissues harvested 6 h post-treatment demonstrated that 15-epi-lipoxin A4 treatment increased Ptgs2 expression in the uterus, placenta and fetal membranes (P < 0.05) and decreased 15-Hpgd expression (P < 0.05) in the placenta and uterus, suggesting that 15-epi-lipoxin A4 may regulate the local production and activity of prostaglandins.

View Article: PubMed Central - PubMed

Affiliation: MRC Centre for Reproductive Health and Tommy's Centre for Maternal and Fetal Health, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK s.rinaldi@ed.ac.uk.

Show MeSH

Related in: MedlinePlus

Effect of pretreatment with 15-epi-lipoxin A4 on mRNA expression of Ptgs2 and 15-Hpgd in the utero-placental tissues. Uterus, placenta and fetal membranes were collected 6 h post-surgery from mice pretreated with vehicle (n = 3) or 2.5 μg 15-epi-lipoxin A4 (n = 4), prior to intrauterine PBS; and in mice pretreated with vehicle (n = 5), 0.25 μg 15-epi-lipoxin A4 (n = 5) or 2.5 μg 15-epi-lipoxin A4 (n = 5), prior to intrauterine LPS administration. The mRNA expression of Ptgs2 and 15-Hpgd was quantified by quantitative real-time PCR. (A) Uterine expression. (B) Placental expression. (C) Expression in the fetal membranes. Data presented as mean fold change ± SEM (error bars); *P < 0.05, **P < 0.01, ***P < 0.001, compared with vehicle; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with LPS.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4381035&req=5

GAU117F3: Effect of pretreatment with 15-epi-lipoxin A4 on mRNA expression of Ptgs2 and 15-Hpgd in the utero-placental tissues. Uterus, placenta and fetal membranes were collected 6 h post-surgery from mice pretreated with vehicle (n = 3) or 2.5 μg 15-epi-lipoxin A4 (n = 4), prior to intrauterine PBS; and in mice pretreated with vehicle (n = 5), 0.25 μg 15-epi-lipoxin A4 (n = 5) or 2.5 μg 15-epi-lipoxin A4 (n = 5), prior to intrauterine LPS administration. The mRNA expression of Ptgs2 and 15-Hpgd was quantified by quantitative real-time PCR. (A) Uterine expression. (B) Placental expression. (C) Expression in the fetal membranes. Data presented as mean fold change ± SEM (error bars); *P < 0.05, **P < 0.01, ***P < 0.001, compared with vehicle; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with LPS.

Mentions: In the uterus, Ptgs2 expression was significantly elevated in response to 2.5 µg 15-epi-lipoxin A4 alone (P < 0.01), LPS alone (P < 0.01), and 0.25 µg and 2.5 µg 15-epi-lipoxin A4 + LPS (P < 0.001; Fig. 3A), compared with the vehicle control group. Co-treatment with 2.5 µg 15-epi-lipoxin A4 and LPS also significantly increased uterine Ptgs2 expression compared with treatment with LPS alone (P < 0.05; Fig. 3A). Conversely, uterine 15-Hpgd expression was significantly reduced in mice treated with 2.5 µg 15-epi-lipoxin A4 prior to intrauterine PBS, compared with vehicle (P < 0.01) and LPS alone (P < 0.05). LPS alone did not significantly alter 15-Hpgd expression; however, mice treated with 0.25 µg 15-epi-lipoxin A4 + LPS and 2.5 µg 15-epi-lipoxin A4 + LPS had significantly reduced uterine 15-Hpgd expression, compared with the vehicle group (P < 0.001). Additionally pretreatment with 0.25 µg 15-epi-lipoxin A4 and 2.5 µg 15-epi-lipoxin A4 prior to intrauterine LPS, significantly reduced uterine expression of 15-Hpgd, compared with LPS alone (P < 0.001; Fig. 3A).Figure 3


15-epi-lipoxin A4 reduces the mortality of prematurely born pups in a mouse model of infection-induced preterm birth.

Rinaldi SF, Catalano RD, Wade J, Rossi AG, Norman JE - Mol. Hum. Reprod. (2015)

Effect of pretreatment with 15-epi-lipoxin A4 on mRNA expression of Ptgs2 and 15-Hpgd in the utero-placental tissues. Uterus, placenta and fetal membranes were collected 6 h post-surgery from mice pretreated with vehicle (n = 3) or 2.5 μg 15-epi-lipoxin A4 (n = 4), prior to intrauterine PBS; and in mice pretreated with vehicle (n = 5), 0.25 μg 15-epi-lipoxin A4 (n = 5) or 2.5 μg 15-epi-lipoxin A4 (n = 5), prior to intrauterine LPS administration. The mRNA expression of Ptgs2 and 15-Hpgd was quantified by quantitative real-time PCR. (A) Uterine expression. (B) Placental expression. (C) Expression in the fetal membranes. Data presented as mean fold change ± SEM (error bars); *P < 0.05, **P < 0.01, ***P < 0.001, compared with vehicle; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with LPS.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4381035&req=5

GAU117F3: Effect of pretreatment with 15-epi-lipoxin A4 on mRNA expression of Ptgs2 and 15-Hpgd in the utero-placental tissues. Uterus, placenta and fetal membranes were collected 6 h post-surgery from mice pretreated with vehicle (n = 3) or 2.5 μg 15-epi-lipoxin A4 (n = 4), prior to intrauterine PBS; and in mice pretreated with vehicle (n = 5), 0.25 μg 15-epi-lipoxin A4 (n = 5) or 2.5 μg 15-epi-lipoxin A4 (n = 5), prior to intrauterine LPS administration. The mRNA expression of Ptgs2 and 15-Hpgd was quantified by quantitative real-time PCR. (A) Uterine expression. (B) Placental expression. (C) Expression in the fetal membranes. Data presented as mean fold change ± SEM (error bars); *P < 0.05, **P < 0.01, ***P < 0.001, compared with vehicle; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with LPS.
Mentions: In the uterus, Ptgs2 expression was significantly elevated in response to 2.5 µg 15-epi-lipoxin A4 alone (P < 0.01), LPS alone (P < 0.01), and 0.25 µg and 2.5 µg 15-epi-lipoxin A4 + LPS (P < 0.001; Fig. 3A), compared with the vehicle control group. Co-treatment with 2.5 µg 15-epi-lipoxin A4 and LPS also significantly increased uterine Ptgs2 expression compared with treatment with LPS alone (P < 0.05; Fig. 3A). Conversely, uterine 15-Hpgd expression was significantly reduced in mice treated with 2.5 µg 15-epi-lipoxin A4 prior to intrauterine PBS, compared with vehicle (P < 0.01) and LPS alone (P < 0.05). LPS alone did not significantly alter 15-Hpgd expression; however, mice treated with 0.25 µg 15-epi-lipoxin A4 + LPS and 2.5 µg 15-epi-lipoxin A4 + LPS had significantly reduced uterine 15-Hpgd expression, compared with the vehicle group (P < 0.001). Additionally pretreatment with 0.25 µg 15-epi-lipoxin A4 and 2.5 µg 15-epi-lipoxin A4 prior to intrauterine LPS, significantly reduced uterine expression of 15-Hpgd, compared with LPS alone (P < 0.001; Fig. 3A).Figure 3

Bottom Line: There are currently few effective therapies and therefore an urgent need for novel treatments.Although pretreatment with 15-epi-lipoxin A4 did not delay LPS-induced PTL, there was a significant reduction in the mortality amongst prematurely delivered pups (defined as delivery within 36 h of surgery) in mice treated with 15-epi-lipoxin A4 prior to LPS treatment, compared with those receiving LPS alone (P < 0.05).Quantitative real-time (QRT)-PCR analysis of utero-placental tissues harvested 6 h post-treatment demonstrated that 15-epi-lipoxin A4 treatment increased Ptgs2 expression in the uterus, placenta and fetal membranes (P < 0.05) and decreased 15-Hpgd expression (P < 0.05) in the placenta and uterus, suggesting that 15-epi-lipoxin A4 may regulate the local production and activity of prostaglandins.

View Article: PubMed Central - PubMed

Affiliation: MRC Centre for Reproductive Health and Tommy's Centre for Maternal and Fetal Health, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK s.rinaldi@ed.ac.uk.

Show MeSH
Related in: MedlinePlus